Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Siegfried Holding AGXSWX:SFZN -0.35%85 3-Year EPS without NRI Growth Rate is 7.60% as of Jun. 2026, which is 59% below its 10-year median of 18.60. GuruFocus rates XSWX:SFZN with a GF Score™ of 85/100 and a GF Value™ of CHF92.52 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 782 Drug Manufacturers companies, Siegfried Holding AG ranks worse than 53.71% on this metric.
During the past 12 months, Siegfried Holding AG's average EPS without NRI Growth Rate was 7.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 7.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 16.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 18.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Siegfried Holding AG was 446.80% per year. The lowest was -78.50% per year. And the median was 18.60% per year.
Siegfried Holding AG (XSWX:SFZN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Siegfried Holding AG 3-Year EPS without NRI Growth Rate Related Terms
XSWX:SFZN vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siegfried Holding AG 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Siegfried Holding AG's 3-Year EPS without NRI Growth Rate falls into.
Siegfried Holding AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.60% mean?
Siegfried Holding AG (XSWX:SFZN) has a 3-Year EPS without NRI Growth Rate of 7.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Siegfried Holding AG and its competitors. This is 59% below median its historical median of 18.60. According to the industry distribution chart, Siegfried Holding AG ranks #420 out of 782 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is Siegfried Holding AG's 3-Year EPS without NRI Growth Rate too high?
Siegfried Holding AG's current 3-Year EPS without NRI Growth Rate of 7.60% is 59% below median its 10-year median of 18.60. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Siegfried Holding AG's value of 7.60% is 22.4% below this industry median. Based on the distribution chart, Siegfried Holding AG ranks #420 out of 782 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Siegfried Holding AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siegfried Holding AG's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Siegfried Holding AG ranks #420 out of 782 companies for 3-Year EPS without NRI Growth Rate. This places Siegfried Holding AG in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Siegfried Holding AG's value of 7.60% is 22.4% below this benchmark. While the company's 10-year median is 18.60 vs. the industry median of 9.80, Siegfried Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 782 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siegfried Holding AG's current 3-Year EPS without NRI Growth Rate of 7.60% is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Siegfried Holding AG and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siegfried Holding AG's current 3-Year EPS without NRI Growth Rate is 7.60%, which is 59% below median its own 10-year median of 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siegfried Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Siegfried Holding AG (XSWX:SFZN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF92.52, compared to a current price of CHF71.05 — trading 23.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.60%, which is 59% below median its 10-year median of 18.60 and 22.4% below the Drug Manufacturers industry median of 9.80. Siegfried Holding AG's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Siegfried Holding AG (XSWX:SFZN), the current 3-Year EPS without NRI Growth Rate is 7.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siegfried Holding AG (XSWX:SFZN) Overvalued in 2026?
Based on GuruFocus' analysis, Siegfried Holding AG stock appears to be undervalued.
The current stock price of CHF71.05 is trading 23.2% below its estimated GF Value™ of CHF92.52.
GuruFocus considers Siegfried Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SFZN:
3-Year EPS without NRI Growth Rate: 7.60% (59% below median its 10-year median of 18.60)
GF Value™: CHF92.52 vs. price of CHF71.05 (23.2% below fair value)
Industry Position: 22.4% below the Drug Manufacturers median (#420 of 782)
No single metric tells the full story. See the XSWX:SFZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
85GF Score
Get the complete analysis for XSWX:SFZN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SFZN has been successfully added to your 
